The significance of HERC5, IFIH1, SAMD4, SEMA3A and MCTP1 genes expression in resistance to cytotoxic drugs in ovarian cancer cell lines

1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34; DOI:10.3322/caac.21551. SiegelRL MillerKD JemalA Cancer statistics, 2019 CA Cancer J Clin 2019 69 1 7 34 10.3322/caac.21551 Open DOISearch in Google Scholar

2 Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14; DOI:10.1016/j.bpobgyn.2016.08.006. WebbPM JordanSJ Epidemiology of epithelial ovarian cancer Best Pract Res Clin Obstet Gynaecol 2017 41 3 14 10.1016/j.bpobgyn.2016.08.006 Open DOISearch in Google Scholar

3 Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian cancer. Annals of Oncology. 2017;28:viii51–6; DOI:10.1093/annonc/mdx441. PignataS C CecereS Du BoisA HarterP HeitzF Treatment of recurrent ovarian cancer Annals of Oncology 2017 28 viii51 6 10.1093/annonc/mdx441 Open DOISearch in Google Scholar

4 Webber K, Friedlander M. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:126–138; DOI:10.1016/j.bpobgyn.2016.11.004. WebberK FriedlanderM Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer Best Pract Res Clin Obstet Gynaecol 2017 41 126 138 10.1016/j.bpobgyn.2016.11.004 Open DOISearch in Google Scholar

5 Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478(1–2):23–43; DOI:10.1016/s0027-5107(01)00141-5. KartalouM EssigmannJM Mechanisms of resistance to cisplatin Mutat Res 2001 478 1–2 23 43 10.1016/s0027-5107(01)00141-5 Open DOISearch in Google Scholar

6 Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 2007;63(1):12–31; DOI:10.1016/j.critrevonc.2007.02.001. StewartDJ Mechanisms of resistance to cisplatin and carboplatin Crit Rev Oncol Hematol 2007 63 1 12 31 10.1016/j.critrevonc.2007.02.001 Open DOISearch in Google Scholar

7 Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998;18(4):259–96; DOI:10.1002/(sici)1098-1128(199807)18:4<259::aid-med3>3.0.co;2-u. JordanA HadfieldJA LawrenceNJ McGownAT Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle Med Res Rev 1998 18 4 259 96 10.1002/(sici)1098-1128(199807)18:4<259::aid-med3>3.0.co;2-u Open DOISearch in Google Scholar

8 Januchowski R, Sterzyńska K, Zaorska K, Sosińska P, Klejewski A, Brązert M, Nowicki M, Zabel M. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines. J Ovarian Res. 2016;9(1):65; DOI:10.1186/s13048-016-0278-z. JanuchowskiR SterzyńskaK ZaorskaK SosińskaP KlejewskiA BrązertM NowickiM ZabelM Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines J Ovarian Res 2016 9 1 65 10.1186/s13048-016-0278-z Open DOISearch in Google Scholar

9 Januchowski R, Wojtowicz K, Andrzejewska M, Zabel M. Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines. Biomed Pharmacother. 2014;68(1):111–7; DOI:10.1016/j.biopha.2013.09.004. JanuchowskiR WojtowiczK AndrzejewskaM ZabelM Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines Biomed Pharmacother 2014 68 1 111 7 10.1016/j.biopha.2013.09.004 Open DOISearch in Google Scholar

10 Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26(6):890–6. DOI:10.1200/JCO.2007.13.6606. FerrandinaG LudovisiM LorussoD PignataS BredaE SavareseA Del MedicoP ScaltritiL KatsarosD PrioloD ScambiaG Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer J Clin Oncol 2008 26 6 890 6 10.1200/JCO.2007.13.6606 Open DOISearch in Google Scholar

11 Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, Stauch M, Paulenz A, Camara O, Keil E, Lichtenegger W. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2008;26(19):3176–82; DOI:10.1200/JCO.2007.15.1258. SehouliJ StengelD Oskay-OezcelikG ZeimetAG SommerH KlareP StauchM PaulenzA CamaraO KeilE LichteneggerW Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group J Clin Oncol 2008 26 19 3176 82 10.1200/JCO.2007.15.1258 18591555 Open DOISearch in Google Scholar

12 Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A. 2002;99(24):15387–92; DOI:10.1073/pnas.242259599. StakerBL HjerrildK FeeseMD BehnkeCA BurginABJr StewartL The mechanism of topoisomerase I poisoning by a camptothecin analog Proc Natl Acad Sci U S A 2002 99 24 15387 92 10.1073/pnas.242259599 13772612426403 Open DOISearch in Google Scholar

13 Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, Scotto KW. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res. 1999;5(11):3352–6. AbolhodaA WilsonAE RossH DanenbergPV BurtM ScottoKW Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin Clin Cancer Res 1999 5 11 3352 6 Search in Google Scholar

14 Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007;26(1):39–57; DOI:10.1007/s10555-007-9042-6. RobeyRW PolgarO DeekenJ ToKW BatesSE ABCG2: determining its relevance in clinical drug resistance Cancer Metastasis Rev 2007 26 1 39 57 10.1007/s10555-007-9042-6 17323127 Open DOISearch in Google Scholar

15 Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M, Zabel M. MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int. 2013;2013:241763; DOI:10.1155/2013/241763. JanuchowskiR WojtowiczK Sujka-KordowskaP AndrzejewskaM ZabelM MDR gene expression analysis of six drug-resistant ovarian cancer cell lines Biomed Res Int 2013 2013 241763; 10.1155/2013/241763 359112923484165 Open DOISearch in Google Scholar

16 Sterzyńska K, Kaźmierczak D, Klejewski A, Świerczewska M, Wojtowicz K, Nowacka M, Brązert J, Nowicki M, Januchowski R. Expression of Osteoblast-Specific Factor 2 (OSF-2, Periostin) Is Associated with Drug Resistance in Ovarian Cancer Cell Lines. Int J Mol Sci. 2019;20(16):3927; DOI:10.3390/ijms20163927. SterzyńskaK KaźmierczakD KlejewskiA ŚwierczewskaM WojtowiczK NowackaM BrązertJ NowickiM JanuchowskiR Expression of Osteoblast-Specific Factor 2 (OSF-2, Periostin) Is Associated with Drug Resistance in Ovarian Cancer Cell Lines Int J Mol Sci 2019 20 16 3927 10.3390/ijms20163927 671921831412536 Open DOISearch in Google Scholar

17 Sterzyńska K, Klejewski A, Wojtowicz K, Świerczewska M, Nowacka M, Kaźmierczak D, Andrzejewska M, Rusek D, Brązert M, Brązert J, Nowicki M, Januchowski R. Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development. Int J Mol Sci. 2018;20(1):54; DOI:10.3390/ijms20010054. SterzyńskaK KlejewskiA WojtowiczK ŚwierczewskaM NowackaM KaźmierczakD AndrzejewskaM RusekD BrązertM BrązertJ NowickiM JanuchowskiR Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development Int J Mol Sci 2018 20 1 54 10.3390/ijms20010054 633735430583585 Open DOISearch in Google Scholar

18 Klejewski A, Sterzyńska K, Wojtowicz K, Świerczewska M, Partyka M, Brązert M, Nowicki M, Zabel M, Januchowski R. The significance of lumican expression in ovarian cancer drug-resistant cell lines. Oncotarget. 2017;8(43):74466–74478; DOI:10.18632/oncotarget.20169. KlejewskiA SterzyńskaK WojtowiczK ŚwierczewskaM PartykaM BrązertM NowickiM ZabelM JanuchowskiR The significance of lumican expression in ovarian cancer drug-resistant cell lines Oncotarget 2017 8 43 74466 74478 10.18632/oncotarget.20169 565035529088800 Open DOISearch in Google Scholar

19 Sterzyńska K, Klejewski A, Wojtowicz K, Świerczewska M, Andrzejewska M, Rusek D, Sobkowski M, Kędzia W, Brązert J, Nowicki M, Januchowski R. The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines. Int J Mol Sci. 2018;19(10):2901; DOI:10.3390/ijms19102901. SterzyńskaK KlejewskiA WojtowiczK ŚwierczewskaM AndrzejewskaM RusekD SobkowskiM KędziaW BrązertJ NowickiM JanuchowskiR The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines Int J Mol Sci 2018 19 10 2901 10.3390/ijms19102901 621324230257426 Open DOISearch in Google Scholar

20 Świerczewska M, Klejewski A, Wojtowicz K, Brązert M, Iżycki D, Nowicki M, Zabel M, Januchowski R. New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines. Molecules. 2017;22(10):1717; DOI:10.3390/molecules22101717. ŚwierczewskaM KlejewskiA WojtowiczK BrązertM IżyckiD NowickiM ZabelM JanuchowskiR New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines Molecules 2017 22 10 1717 10.3390/molecules22101717 615155829027969 Open DOISearch in Google Scholar

21 Klejewski A, Świerczewska M, Zaorska K, Brązert M, Nowicki M, Zabel M, Januchowski R. New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines. Anticancer Res. 2017;37(4):1625–1636; DOI:10.21873/anticanres.11493. KlejewskiA ŚwierczewskaM ZaorskaK BrązertM NowickiM ZabelM JanuchowskiR New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines Anticancer Res 2017 37 4 1625 1636 10.21873/anticanres.11493 28373423 Open DOISearch in Google Scholar

22 Świerczewska M, Klejewski A, Brązert M, Kaźmierczak D, Iżycki D, Nowicki M, Zabel M, Januchowski R. New and Old Genes Associated with Primary and Established Responses to Paclitaxel Treatment in Ovarian Cancer Cell Lines. Molecules. 2018;23(4):891; DOI:10.3390/molecules23040891. ŚwierczewskaM KlejewskiA BrązertM KaźmierczakD IżyckiD NowickiM ZabelM JanuchowskiR New and Old Genes Associated with Primary and Established Responses to Paclitaxel Treatment in Ovarian Cancer Cell Lines Molecules 2018 23 4 891 10.3390/molecules23040891 601764129649113 Open DOISearch in Google Scholar

23 Wong JJ, Pung YF, Sze NS, Chin KC. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc Natl Acad Sci U S A. 2006;103(28):10735–40; DOI:10.1073/pnas.0600397103. WongJJ PungYF SzeNS ChinKC HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets Proc Natl Acad Sci U S A 2006 103 28 10735 40 10.1073/pnas.0600397103 148441716815975 Open DOISearch in Google Scholar

24 Huang YF, Bulavin DV. Oncogene-mediated regulation of p53 ISGylation and functions. Oncotarget. 2014;5(14):5808–18; DOI:10.18632/oncotarget.2199. HuangYF BulavinDV Oncogene-mediated regulation of p53 ISGylation and functions Oncotarget 2014 5 14 5808 18 10.18632/oncotarget.2199 417063125071020 Open DOISearch in Google Scholar

25 Kiessling A, Hogrefe C, Erb S, Bobach C, Fuessel S, Wessjohann L, Seliger B. Expression, regulation and function of the ISGylation system in prostate cancer. Oncogene. 2009;28(28):2606–20; DOI:10.1038/onc.2009.115. KiesslingA HogrefeC ErbS BobachC FuesselS WessjohannL SeligerB Expression, regulation and function of the ISGylation system in prostate cancer Oncogene 2009 28 28 2606 20 10.1038/onc.2009.115 19430494 Open DOISearch in Google Scholar

26 Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, Akira S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441(7089):101–5; DOI:10.1038/nature04734. KatoH TakeuchiO SatoS YoneyamaM YamamotoM MatsuiK UematsuS JungA KawaiT IshiiKJ YamaguchiO OtsuK TsujimuraT KohCS Reis e SousaC MatsuuraY FujitaT AkiraS Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses Nature 2006 441 7089 101 5 10.1038/nature04734 16625202 Open DOISearch in Google Scholar

27 Lin L, Su Z, Lebedeva IV, Gupta P, Boukerche H, Rai T, Barber GN, Dent P, Sarkar D, Fisher PB. Activation of Ras/Raf protects cells from melanoma differentiation-associated gene-5-induced apoptosis. Cell Death Differ. 2006;13(11):1982–93; DOI:10.1038/sj.cdd.4401899. LinL SuZ LebedevaIV GuptaP BoukercheH RaiT BarberGN DentP SarkarD FisherPB Activation of Ras/Raf protects cells from melanoma differentiation-associated gene-5-induced apoptosis Cell Death Differ 2006 13 11 1982 93 10.1038/sj.cdd.4401899 16575407 Open DOISearch in Google Scholar

28 Pinder BD, Smibert CA. Smaug: an unexpected journey into the mechanisms of post-transcriptional regulation. Fly (Austin). 2013;7(3):142–5; DOI:10.4161/fly.24336. PinderBD SmibertCA Smaug: an unexpected journey into the mechanisms of post-transcriptional regulation Fly (Austin) 2013 7 3 142 5 10.4161/fly.24336 404984523519205 Open DOISearch in Google Scholar

29 Aviv T, Lin Z, Lau S, Rendl LM, Sicheri F, Smibert CA. The RNA-binding SAM domain of Smaug defines a new family of post-transcriptional regulators. Nat Struct Biol. 2003;10(8):614–21; DOI:10.1038/nsb956. AvivT LinZ LauS RendlLM SicheriF SmibertCA The RNA-binding SAM domain of Smaug defines a new family of post-transcriptional regulators Nat Struct Biol 2003 10 8 614 21 10.1038/nsb956 12858164 Open DOISearch in Google Scholar

30 Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, Seano G, Serini G, Bussolino F, Giraudo E. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest. 2009;119(11):3356–72; DOI:10.1172/JCI36308. MaioneF MollaF MedaC LatiniR ZentilinL GiaccaM SeanoG SeriniG BussolinoF GiraudoE Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models J Clin Invest 2009 119 11 3356 72 10.1172/JCI36308 276918719809158 Open DOISearch in Google Scholar

31 Tang C, Gao X, Liu H, Jiang T, Zhai X. Decreased expression of SEMA3A is associated with poor prognosis in gastric carcinoma. Int J Clin Exp Pathol. 2014;7(8):4782–94. TangC GaoX LiuH JiangT ZhaiX Decreased expression of SEMA3A is associated with poor prognosis in gastric carcinoma Int J Clin Exp Pathol 2014 7 8 4782 94 Search in Google Scholar

32 Song X, Zhang W, Zhang Y, Zhang H, Fu Z, Ye J, Liu L, Song X, Wu Y. Expression of semaphorin 3A and neuropilin 1 with clinicopathological features and survival in human tongue cancer. Med Oral Patol Oral Cir Bucal. 2012;17(6):e962–8; DOI:10.4317/medoral.18168. SongX ZhangW ZhangY ZhangH FuZ YeJ LiuL SongX WuY Expression of semaphorin 3A and neuropilin 1 with clinicopathological features and survival in human tongue cancer Med Oral Patol Oral Cir Bucal 2012 17 6 e962 8 10.4317/medoral.18168 350571722926477 Open DOISearch in Google Scholar

33 Jiang H, Qi L, Wang F, Sun Z, Huang Z, Xi Q. Decreased semaphorin 3A expression is associated with a poor prognosis in patients with epithelial ovarian carcinoma. Int J Mol Med. 2015;35(5):1374–80; DOI:10.3892/ijmm.2015.2142. JiangH QiL WangF SunZ HuangZ XiQ Decreased semaphorin 3A expression is associated with a poor prognosis in patients with epithelial ovarian carcinoma Int J Mol Med 2015 35 5 1374 80 10.3892/ijmm.2015.2142 Open DOISearch in Google Scholar

34 Shin OH, Han W, Wang Y, Südhof TC. Evolutionarily conserved multiple C2 domain proteins with two transmembrane regions (MCTPs) and unusual Ca²⁺ binding properties. J Biol Chem. 2005;280(2):1641–51; DOI:10.1074/jbc.M407305200. ShinOH HanW WangY SüdhofTC Evolutionarily conserved multiple C2 domain proteins with two transmembrane regions (MCTPs) and unusual Ca²⁺ binding properties J Biol Chem 2005 280 2 1641 51 10.1074/jbc.M407305200 Open DOISearch in Google Scholar

35 Qiu L, Yu H, Liang F. Multiple C2 domains transmembrane protein 1 is expressed in CNS neurons and possibly regulates cellular vesicle retrieval and oxidative stress. J Neurochem. 2015;135(3):492–507; DOI:10.1111/jnc.13251. QiuL YuH LiangF Multiple C2 domains transmembrane protein 1 is expressed in CNS neurons and possibly regulates cellular vesicle retrieval and oxidative stress J Neurochem 2015 135 3 492 507 10.1111/jnc.13251 Open DOISearch in Google Scholar

36 Abdel-Rahman WM, Lotsari-Salomaa JE, Kaur S, Niskakoski A, Knuutila S, Järvinen H, Mecklin JP, Peltomäki P. The Role of Chromosomal Instability and Epigenetics in Colorectal Cancers Lacking β-Catenin/TCF Regulated Transcription. Gastroenterol Res Pract. 2016;2016:6089658; DOI:10.1155/2016/6089658. Abdel-RahmanWM Lotsari-SalomaaJE KaurS NiskakoskiA KnuutilaS JärvinenH MecklinJP PeltomäkiP The Role of Chromosomal Instability and Epigenetics in Colorectal Cancers Lacking β-Catenin/TCF Regulated Transcription Gastroenterol Res Pract 2016 2016 6089658; 10.1155/2016/6089658 Open DOISearch in Google Scholar

37 Hernandez L, Kim MK, Lyle LT, Bunch KP, House CD, Ning F, Noonan AM, Annunziata CM. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol Oncol. 2016;142(2):332–40; DOI:10.1016/j.ygyno.2016.05.028. HernandezL KimMK LyleLT BunchKP HouseCD NingF NoonanAM AnnunziataCM Characterization of ovarian cancer cell lines as in vivo models for preclinical studies Gynecol Oncol 2016 142 2 332 40 10.1016/j.ygyno.2016.05.028 Open DOISearch in Google Scholar

38 Stukova M, Hall MD, Tsotsoros SD, Madigan JP, Farrell NP, Gottesman MM. Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients. J Inorg Biochem. 2015;149:45–8; DOI:10.1016/j.jinorgbio.2015.05.003. StukovaM HallMD TsotsorosSD MadiganJP FarrellNP GottesmanMM Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients J Inorg Biochem 2015 149 45 8 10.1016/j.jinorgbio.2015.05.003 Open DOISearch in Google Scholar

39 Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 1983;43(11):5379–89. HamiltonTC YoungRC McKoyWM GrotzingerKR GreenJA ChuEW Whang-PengJ RoganAM GreenWR OzolsRF Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors Cancer Res 1983 43 11 5379 89 Search in Google Scholar

40 Kiessling A, Hogrefe C, Erb S, Bobach C, Fuessel S, Wessjohann L, Seliger B. Expression, regulation and function of the ISGylation system in prostate cancer. Oncogene. 2009;28(28):2606–20; DOI:10.1038/onc.2009.115. KiesslingA HogrefeC ErbS BobachC FuesselS WessjohannL SeligerB Expression, regulation and function of the ISGylation system in prostate cancer Oncogene 2009 28 28 2606 20 10.1038/onc.2009.115 Open DOISearch in Google Scholar

41 Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, Jaffee E, Ryu B, Jones J, Eshleman JR, Yeo CJ, Cameron JL, Kern SE, Hruban RH, Brown PO, Goggins M. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol. 2003;162(4):1151–62; DOI:10.1016/S0002-9440(10)63911-9. Iacobuzio-DonahueCA MaitraA OlsenM LoweAW van HeekNT RostyC WalterK SatoN ParkerA AshfaqR JaffeeE RyuB JonesJ EshlemanJR YeoCJ CameronJL KernSE HrubanRH BrownPO GogginsM Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays Am J Pathol 2003 162 4 1151 62 10.1016/S0002-9440(10)63911-9 Open DOISearch in Google Scholar

42 Desai SD, Reed RE, Burks J, Wood LM, Pullikuth AK, Haas AL, Liu LF, Breslin JW, Meiners S, Sankar S. ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Exp Biol Med (Maywood). 2012;237(1):38–49; DOI:10.1258/ebm.2011.011236. DesaiSD ReedRE BurksJ WoodLM PullikuthAK HaasAL LiuLF BreslinJW MeinersS SankarS ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells Exp Biol Med (Maywood) 2012 237 1 38 49 10.1258/ebm.2011.011236 22185919 Open DOISearch in Google Scholar

43 Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF. Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer. 2006;94(10):1465–71; DOI:10.1038/sj.bjc.6603099. AndersenJB AaboeM BordenEC GoloubevaOG HasselBA OrntoftTF Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer Br J Cancer 2006 94 10 1465 71 10.1038/sj.bjc.6603099 236127816641915 Open DOISearch in Google Scholar

44 Wang Y, Ding Q, Xu T, Li CY, Zhou DD, Zhang L. HZ-6d targeted HERC5 to regulate p53 ISGylation in human hepatocellular carcinoma. Toxicol Appl Pharmacol. 2017;334:180–191; DOI:10.1016/j.taap.2017.09.011. WangY DingQ XuT LiCY ZhouDD ZhangL HZ-6d targeted HERC5 to regulate p53 ISGylation in human hepatocellular carcinoma Toxicol Appl Pharmacol 2017 334 180 191 10.1016/j.taap.2017.09.011 28919514 Open DOISearch in Google Scholar

45 Tang J, Yang Q, Cui Q, Zhang D, Kong D, Liao X, Ren J, Gong Y, Wu G. Weighted gene correlation network analysis identifies RSAD2, HERC5, and CCL8 as prognostic candidates for breast cancer. J Cell Physiol. 2020;235(1):394–407; DOI:10.1002/jcp.28980. TangJ YangQ CuiQ ZhangD KongD LiaoX RenJ GongY WuG Weighted gene correlation network analysis identifies RSAD2, HERC5, and CCL8 as prognostic candidates for breast cancer J Cell Physiol 2020 235 1 394 407 10.1002/jcp.28980 31225658 Open DOISearch in Google Scholar

46 Marín-Aguilera M, Codony-Servat J, Kalko SG, Fernández PL, Bermudo R, Buxo E, Ribal MJ, Gascón P, Mellado B. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther. 2012;11(2):329–39; DOI:10.1158/1535-7163.MCT-11-0289. Marín-AguileraM Codony-ServatJ KalkoSG FernándezPL BermudoR BuxoE RibalMJ GascónP MelladoB Identification of docetaxel resistance genes in castration-resistant prostate cancer Mol Cancer Ther 2012 11 2 329 39 10.1158/1535-7163.MCT-11-0289 22027694 Open DOISearch in Google Scholar

47 Hou DL, Chen L, Liu B, Song LN, Fang T. Identification of common gene networks responsive to radiotherapy in human cancer cells. Cancer Gene Ther. 2014;21(12):542–8; DOI:10.1038/cgt.2014.62. HouDL ChenL LiuB SongLN FangT Identification of common gene networks responsive to radiotherapy in human cancer cells Cancer Gene Ther 2014 21 12 542 8 10.1038/cgt.2014.62 25412644 Open DOISearch in Google Scholar

48 Huang C, Wang Y, Huang JH, Liu W. Sema3A drastically suppresses tumor growth in oral cancer Xenograft model of mice. BMC Pharmacol Toxicol. 2017 Jul 6;18(1):55; DOI:10.1186/s40360-017-0163-4. HuangC WangY HuangJH LiuW Sema3A drastically suppresses tumor growth in oral cancer Xenograft model of mice BMC Pharmacol Toxicol 2017 Jul 6 18 1 55 10.1186/s40360-017-0163-4 550144328683823 Open DOISearch in Google Scholar

49 Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008;10:e19; DOI:10.1017/S1462399408000744. AbukhdeirAM ParkBH P21 and p27: roles in carcinogenesis and drug resistance Expert Rev Mol Med 2008 10 e19 10.1017/S1462399408000744 267895618590585 Open DOISearch in Google Scholar

50 Świerczewska M, Sterzyńska K, Wojtowicz K, Kaźmierczak D, Iżycki D, Nowicki M, Zabel M, Januchowski R. PTPRK Expression Is Down-regulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations. Int J Mol Sci. 2019;20(8):2053; DOI:10.3390/ijms20082053. ŚwierczewskaM SterzyńskaK WojtowiczK KaźmierczakD IżyckiD NowickiM ZabelM JanuchowskiR PTPRK Expression Is Down-regulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations Int J Mol Sci 2019 20 8 2053 10.3390/ijms20082053 651525331027318 Open DOISearch in Google Scholar